Australia: Lundbeck fight back in relation to its Lexapro Patent

Life Sciences Update
Last Updated: 10 October 2011
Article by Simone Mitchell

The ongoing saga of Lundbeck's fight for its patent on the widely used anti-depressant Lexapro has culminated in an extraordinary decision by the Patents Office (Alphapharm Pty Ltd, Sigma Pharmaceuticals (Australia) Pty Ltd, Apotex Pty Ltd, Sandoz Pty Ltd v H Lundbeck A/s [2011] APO 36). This case has seen Lundbeck secure an extension of time of some 121 months to file a section 70 application in order to extend the term of one of its patents.

The fact an extension of term has been granted is not in itself unusual. The Commissioner has previously granted an extension of time in relation to section 70 applications. What places this decision in the realm of the extraordinary is the length of the extension, probably the longest extension ever granted by the Patents Office. This is combined with the fact that the decision to grant the extension was made at a time when the relevant patent had already expired and when there was a number of generic entrants, some of which have been listed on the PBS for more than two years.


The patent in issue is Lundbeck's patent number 623144 entitled '(+)-enantiomer of citalopram and the process of the preparation thereof'. The (+)-enantiomer salt (escitalopram oxalate) is marketed by Lundbeck under the brand name Lexapro.


Section 70 of the Patents Act 1990 (Act) outlines the requirements for an application for an extension of term of a pharmaceutical substance.

Further, the Act sets out the timing requirements for filing an application under section 70. It provides that an application for an extension of term must be made during the term of the patent and within six months after the latest of the following dates:

  • the date the patent was granted
  • the date of commencement of the first inclusion in the ARTG of goods that contain, or consist of, any pharmaceutical substances reference to in subsection 70(3); or
  • the date of commencement of this section.


The patent has been subject of numerous legal challenges, not only to an extension of term that was previously granted by the Patents Office but also to the validity of the patent itself. These challenges ultimately culminated in a special leave application to the High Court, which was refused on 11 December 2010.

Although the validity of the patent had been upheld on 11 June 2009, the Full Federal Court1 held that the extension of term of the patent that had been granted originally had been referenced to the wrong pharmaceutical and, consequently, the register was rectified to remove the previously granted extension of term.

The Full Federal Court found that Lundbeck's pharmaceutical Citalopram, which is marketed under the brand name Cirpamil, necessarily contained the '(+)-enantiomer of citalopram' as it is a racemate salt (ie it existed as a mixture of (+)-citalopram and (-)- citalopram). Consequently, for the purposes of section 70 and 71 of the Act, the 'first goods included on the ARTG that contained, or consisted of' (+)-citalopram was Cipramil. Cipramil was first registered on the ARTG on 9 December 1997. As Lundbeck's original extensionof- term application was referenced to Lexapro (the (+) enantiomer of citalopram) and filed on 22 December 2003, the Full Federal Court1 held that the application was out of time and that the extension should be removed.


As a consequence of the removal of the extension of term, the patent expired on 13 June 2009. However, on 12 June 2009, one day prior to the expiry of the patent, Lundbeck filed a second extension-of-term application in relation to the patent based on Cipramil together with an extensionof- time application under section 223 of the Act.

The applications were opposed by four parties, who had launched generic products on the expiry of the original patent term.

Section 223 of the Act allows an extension of time to do a 'relevant act'. The opponents argued that Lundbeck could not seek an extension of time in relation to a section 70 application. Regulation 22.11(4) specifically excludes the following act for the purposes of section 223:

'Filing, during the term of a standard patent as required by subsection 71(2) of the Patents Act, an application under section 70 (1) of the Act for an extension of term of the patent.'

Although the hearing officer acknowledged that there was at least an argument that, when read literally, the regulation excluded an extension-of-time application in relation to an extension-of-term application, the hearing officer found that the regulation should be construed in a purposive manner that allowed an extension of time application to be filed 'during the term of the patent'.

As Lundbeck had filed its extension-of-term application a day prior to the patent expiring, it was entitled to have its section 223 request determined.


Pursuant to section 223 of the Act, in obtaining an extension of time an applicant must show that a relevant act was not done within a certain time because of:

  • an error or omission by the person concerned or by his agent or attorney; or
  • circumstances beyond the control of the person concerned.

The hearing officer found that there was a causative error that enlivened section 223 of the Act because Lundbeck had mistakenly thought that Cipramil was not a relevant good in relation to the patent. Further, the hearing officer found that Lundbeck continued to hold this belief until at least 11 June 2009 when the Full Federal Court handed down its decision. This is despite the fact that the Full Federal Court ultimately affirmed the first instance decision, which was issued on 24 April 2008.


As section 223 of the Act is a discretionary remedy, the hearing officer considered a number of discretionary factors and ultimately determined that the extension of time should be granted despite the fact that Lundbeck sought an extension of an unprecedented 121 months.

The discretionary factors that were considered include:

  • Whether there had been unreasonable delay - The hearing officer referred to the Federal Court decision of Merck v Arrow in which it was held that an ARTG registered product that 'contained' the claimed product (even as an impurity) was sufficient for the purposes of section 70(3) of the Act. Although this decision was issued in November 2005, the Commissioner found that there was still uncertainty in the field and that given the decision had been undefended and given Lundbeck's strong belief that it would win its case on appeal, it was reasonable for Lundbeck to wait for the appeal process to be finalised. In any event, the Commissioner would not have been able to make a decision on an alternative section 70 application until the fate of the first extension was known. Therefore, the hearing officer was satisfied that the patentee did not cause any unreasonable delay.
  • The patentee's interests - The hearing officer took into account the fact that if the patent were extended based on the ARTG registration of Cipramil, this would add an additional 3.5 years to the patent and the effective patent term would be 9.5 years. Consequently, the extended term would be closer to a 15-year effective patent term intended by the extension-of-term scheme introduced into the Act and would better compensate Lundbeck.
  • Third-party interests - As outlined above, since the expiry of the original term of the patent on 13 June 2009, third parties commenced selling their generic escitalopram products and a number of those products had been listed on the PBS. A number of these parties opposed the section 223 application on the basis that the current situation would not have arisen if Lundbeck acted sooner, as they would have been able to delay the launch of their products until after the extension-of-term application had been determined. Instead, Lundbeck filed its section 223 application on the day prior to the expiry of the original term of the patent and the application was only advertised after the expiry of the patent on 23 July 2009. However, the hearing officer held that third parties entered the market as soon as the original term had expired to obtain a 'market advance' and this entry was a) within any potentially available statutory extension period and b) prior to the patentee exhausting all avenues of appeal. Consequently, the third parties launched in the face of a known commercial risk and the disadvantages of doing so could not be attributed to any delay occasioned by Lundbeck.
  • Public interest - The opponents argued that there was a significant public interest against extending the term of a patent that had expired. Particularly, that this would force competitors from the market, which would significantly increase the cost of the drug. Although the Commissioner accepted that the cost of the drug was likely to increase, she noted that this would only be for a short time (being 3.5 years) and would always have been the case if the correct extension had been granted in the first place.


The practical effect of this decision is somewhat unclear. In her decision, the hearing officer clearly states that she could not have been able to make a decision on an alternative section 70 application until the fate of the first extension was known. Consequently, unless an extension-of-term application has been successfully challenged, the Commissioner is not able to determine an alternative section 70 application. This places a patentee in a predicament where an extension of term has been granted in relation to an inappropriate drug but the validity of the extension has not been challenged by any third party.

However, if an application for an extension of time to file an alternative section 70 application is not made immediately on becoming aware that the extension of term was based on an incorrectly referenced drug, an issue of unreasonable delay will arise. This is a disentitling factor when determining whether an extension of time will be granted.

In circumstances where the patentee has inadvertently referenced the wrong drug, it should carefully consider what steps should be taken to protect its interests.

This decision has been appealed and we will update you in relation to that appeal.


1Lundbeck A/S v Alphapharm Pty Ltd [2009] FCAFC 70

© DLA Piper

This publication is intended as a general overview and discussion of the subjects dealt with. It is not intended to be, and should not used as, a substitute for taking legal advice in any specific situation. DLA Piper Australia will accept no responsibility for any actions taken or not taken on the basis of this publication.

DLA Piper Australia is part of DLA Piper, a global law firm, operating through various separate and distinct legal entities. For further information, please refer to

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.